Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 3/20 | 0.76 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.76 |
| ▸ | ESR1 | P03372 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 2/20 | 0.69 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.69 |
| ▸ | SHBG | P04278 | 1/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | SNCA | P37840 | 1/20 | 0.69 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.69 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.69 |
| ▸ | STS | P08842 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521870 | 1.00 | ABCC4 (0.76) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL345571 | 0.91 | STS (0.76) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL6440061 | 0.91 | KDM4E (0.76) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL6369320 | 0.91 | STS (0.76) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL2522894 | 0.90 | ABCC4 (0.71) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL6369302 | 0.89 | ESR1 (0.66) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL8214049 | 0.89 | ESR1 (0.66) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL3371578 | 0.89 | ESR1 (0.66) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL3369399 | 0.89 | ESR1 (0.66) | ABCC4ABCC1ESR1LMNAESR2 | |
| SCHEMBL9397340 | 0.88 | ESR1 (0.77) | ABCC4ABCC1ESR1LMNAESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-10-05 | — | — | US | claimed |
| CN-115835886-A | GPER proteolytic targeting chimeras | 衣阿华大学研究基金会 | 2023-03-21 | — | — | CN | claimed |
| EP-4138921-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | University Of Iowa Research Foundation (US) | 2023-03-01 | — | — | EP | claimed |
| WO-2021217036-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | SALEM ALIASGER K (US) | 2021-10-28 | — | — | WO | claimed |
| WO-2021123830-A1 | METHOD OF DETERMINING RISK OF FETAL SIZE ABNORMALITY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2021-06-24 | — | — | WO | claimed |
| EP-1549292-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | Schering Aktiengesellschaft (DE) | 2005-07-06 | — | — | EP | claimed |
| EP-0858506-A4 | GENETIC INDUCTION OF RECEPTORS FOR TARGETED RADIOTHERAPY | UAB RESEARCH FOUNDATION (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040223983-A1 | Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | claimed |
| WO-2004032897-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | WO | claimed |
| US-5981504-A | ADMINISTERING TO THE PATIENT A TRANSDUCED GENE ENCODING A MEMBRANE EXPRESSED PROTEIN UNIQUE TO THE TUMOR AND TREATING THE PATIENT WITH AN EFFECTIVE DOSE OF A RADIOLABELED LIGAND WHICH SPECIFICALLY BINDS TO THE EXPRESSED PROTEIN | UAB RESEARCH FOUNDATION (US) | 1999-11-09 | — | — | US | claimed |
| US-5902583-A | RADIOLABELED LIGAND LOCALIZATION TO A SOLID TUMOR IN VIVO: TRANSDUCING A TUMOR IN VIVO WITH A GENE ENCODING A MEMBRANE EXPRESSED PROTEIN UNIQUE TO THE TUMOR, ADMINISTERING A RADIOLABELED LIGAND THAT SPECIFICALLY BINDS TO THAT PROTEIN | UAB RESEARCH FOUNDATION (US) | 1999-05-11 | — | — | US | claimed |
| EP-0858506-A2 | GENETIC INDUCTION OF RECEPTORS FOR TARGETED RADIOTHERAPY | THE UAB RESEARCH FOUNDATION (US) | 1998-08-19 | — | — | EP | claimed |
| WO-1997016221-A2 | GENETIC INDUCTION OF RECEPTORS FOR TARGETED RADIOTHERAPY | THE UAB RESEARCH FOUNDATION (US) | 1997-05-09 | — | — | WO | claimed |
| US-4888163-A | ANTIESTRIOL-3-SULFATE ANTIBODY | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1989-12-19 | — | — | US | claimed |
| EP-0178683-B1 | IMUNOASSAY FOR ESTRIOL-3-SULFATE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1989-08-09 | — | — | EP | claimed |
| US-4740476-A | Immunoassay for estriol-3-sulfate | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1988-04-26 | — | — | US | claimed |
| US-4637985-A | BINDING ASSAY USING A LABELLED CONJUGATE CAPABLE OF EMITTING DELAYED LUMINESCENCE | INTERNATIONALE OCTROOI MAATSCHAPPIJ "OCTROPA" B.V. (NL) | 1987-01-20 | — | — | US | claimed |
| EP-0200960-A1 | Total estriol fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1986-11-12 | — | — | EP | claimed |
| EP-0178683-A1 | Imunoassay for estriol-3-sulfate | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1986-04-23 | — | — | EP | claimed |
| EP-0104926-A2 | Assay processes and materials therefor | UNILEVER PLC (GB) | 1984-04-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | GPER1, ESR1, ADRM1 | ABCC4 3035/4885ABCC1 2895/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.